Wyeth Ends Temsirolimus Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm cites inadequate efficacy results from an interim analysis of a Phase III breast cancer trial; other oncology trials for temsirolimus are ongoing.
You may also be interested in...
Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use
CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.